Providers

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

Democratic Doctors Caucus June 11 Press Conference
Democratic Doctors Caucus Reaffirms EMTALA Amid Trump's CMS Policy Reversal on Abortion Care

June 18th 2025

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

A comprehensive home-based program integrating weekly telecounseling and individually tailored breathing exercise training reduced hospitalizations among patients with COPD. | Image credit: Ahmad - stock.adobe.com
Telehealth Model Reduces Hospital Admissions in COPD

June 18th 2025

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 18th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo